Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert J Motzer

Showing results (51-60 of 436) with videos related to

Pageof 44
Sort By:
Nature Reviews. Urology|November 12, 2022
Adjuvant therapy options in renal cell carcinoma - targeting the metastatic cascadeKelly N Fitzgerald, Robert J Motzer, Chung-Han Lee
Nature Reviews. Urology|June 22, 2016
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinomaMaria I Carlo, Martin H Voss, Robert J Motzer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2006
Medullary renal cell carcinoma and response to therapy with bortezomibEllen A Ronnen, G Varuni Kondagunta, Robert J Motzer
Nature Reviews. Clinical Oncology|April 18, 2019
Towards individualized therapy for metastatic renal cell carcinomaRitesh R Kotecha, Robert J Motzer, Martin H Voss
Cancer Journal (Sudbury, Mass.)|July 23, 2013
Novel approaches targeting the vascular endothelial growth factor axis in renal cell carcinomaMartin H Voss, James J Hsieh, Robert J Motzer
Investigational New Drugs|August 31, 2002
Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinomaJacqueline Vuky, Richard Yu, Lawrence Schwartz, et al.
BJU International|July 27, 2005
Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future developmentBrian I Rini, Jeffrey A Sosman, Robert J Motzer
Nature Reviews. Clinical Oncology|April 27, 2019
Author Correction: Towards individualized therapy for metastatic renal cell carcinomaRitesh R Kotecha, Robert J Motzer, Martin H Voss
Nature Clinical Practice. Urology|December 13, 2007
Is high-dose chemotherapy effective in patients with relapsed or refractory germ cell tumors?Darren R Feldman, Robert J Motzer, Dean F Bajorin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2006
Advances in urologic oncology: results progress from successful interdisciplinary researchDean F Bajorin, Robert J Motzer, George J Bosl
Pageof 44

Showing results (51-60 of 436) with videos related to

Sort By:
Pageof 44
Nature Reviews. Urology|November 12, 2022
Adjuvant therapy options in renal cell carcinoma - targeting the metastatic cascadeKelly N Fitzgerald, Robert J Motzer, Chung-Han Lee
Nature Reviews. Urology|June 22, 2016
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinomaMaria I Carlo, Martin H Voss, Robert J Motzer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2006
Medullary renal cell carcinoma and response to therapy with bortezomibEllen A Ronnen, G Varuni Kondagunta, Robert J Motzer
Nature Reviews. Clinical Oncology|April 18, 2019
Towards individualized therapy for metastatic renal cell carcinomaRitesh R Kotecha, Robert J Motzer, Martin H Voss
Cancer Journal (Sudbury, Mass.)|July 23, 2013
Novel approaches targeting the vascular endothelial growth factor axis in renal cell carcinomaMartin H Voss, James J Hsieh, Robert J Motzer
Investigational New Drugs|August 31, 2002
Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinomaJacqueline Vuky, Richard Yu, Lawrence Schwartz, et al.
BJU International|July 27, 2005
Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future developmentBrian I Rini, Jeffrey A Sosman, Robert J Motzer
Nature Reviews. Clinical Oncology|April 27, 2019
Author Correction: Towards individualized therapy for metastatic renal cell carcinomaRitesh R Kotecha, Robert J Motzer, Martin H Voss
Nature Clinical Practice. Urology|December 13, 2007
Is high-dose chemotherapy effective in patients with relapsed or refractory germ cell tumors?Darren R Feldman, Robert J Motzer, Dean F Bajorin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2006
Advances in urologic oncology: results progress from successful interdisciplinary researchDean F Bajorin, Robert J Motzer, George J Bosl
Pageof 44